Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Sep. 2015, Dyaxspent$0.39 Mil on purchasing property, plant, equipment.
It gained$0.00 Mil from selling property, plant, and equipment.
It spent$0.00 Mil on purchasing business.
It gained$0.00 Mil from selling business.
It spent$19.02 Mil on purchasing investments.
It gained$94.03 Mil from selling investments.
It paid$0.00Mil for net Intangibles purchase and sale.
And it paid$0.00 Mil for other investing activities.
In all, Dyaxgained$74.62 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Sep. 2015.
Dyax Cash Flow from Investing Historical Data
The historical data trend for Dyax's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Dyax's Cash Flow from Investing for the fiscal year that ended in Dec. 2014 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyax (NAS:DYAX) Cash Flow from Investing Explanation
Dyax's purchase of property, plant, equipment for the
three
months ended in Sep. 2015 was $-0.39 Mil. It means Dyax spent $0.39 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Dyax's sale of property, plant, equipment for the
three
months ended in Sep. 2015 was $0.00 Mil. It means Dyax gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Dyax's purchase of business for the
three
months ended in Sep. 2015 was $0.00 Mil. It means Dyax spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Dyax's sale of business for the
three
months ended in Sep. 2015 was $0.00 Mil. It means Dyax gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Dyax's purchase of investment for the
three
months ended in Sep. 2015 was $-19.02 Mil. It means Dyax spent {stock_data.stock.currency_symbol}}19.02 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Dyax's sale of investment for the
three
months ended in Sep. 2015 was $94.03 Mil. It means Dyax gained $94.03 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Dyax's net Intangibles purchase and sale for the
three
months ended in Sep. 2015 was $0.00 Mil.
It means Dyax paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Dyax's cash from discontinued investing activities for the
three
months ended in Sep. 2015 was 0.00 Mil.
It means Dyax paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Dyax's cash from other investing activities for the
three
months ended in Sep. 2015 was $0.00 Mil.
It means Dyax paid $0.00 Mil for other investing activities.
Dyax Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of Dyax's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DYAX has been successfully added to your 